Eterna Therapeutics (Eterna Therapeutics) Total Revenue Growth Rate (Future 3Y To 5Y Est) : N/A (As of May. 26, 2024)

View and export this data going back to 2021. Start your Free Trial

What is Eterna Therapeutics Total Revenue Growth Rate (Future 3Y To 5Y Est)?

Total Revenue Growth Rate (Future 3Y To 5Y Est) is the average growth rate of total revenue estimates over a 3-year to 5-year period.

As of today, Eterna Therapeutics's Total Revenue Growth Rate (Future 3Y To 5Y Est) is N/A.

Competitive Comparison of Eterna Therapeutics's Total Revenue Growth Rate (Future 3Y To 5Y Est)

For the Biotechnology subindustry, Eterna Therapeutics's Total Revenue Growth Rate (Future 3Y To 5Y Est), along with its competitors' market caps and Total Revenue Growth Rate (Future 3Y To 5Y Est) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Eterna Therapeutics's Total Revenue Growth Rate (Future 3Y To 5Y Est) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Eterna Therapeutics's Total Revenue Growth Rate (Future 3Y To 5Y Est) distribution charts can be found below:

* The bar in red indicates where Eterna Therapeutics's Total Revenue Growth Rate (Future 3Y To 5Y Est) falls into.

Eterna Therapeutics (NAS:ERNA) Total Revenue Growth Rate (Future 3Y To 5Y Est) Explanation

Total Revenue Growth Rate (Future 3Y To 5Y Est) is the growth rate of total revenue estimates over a 3-year to 5-year period. This data is provided directly by our trusted data vendors Refinitiv or Morningstar.

In situations where both vendors do not directly provide the growth rate data, we use the most recent annual revenue for the current year and estimated future revenue figures provided by the vendor to calculate the growth rate. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average total revenue estimates growth rate.

Eterna Therapeutics Total Revenue Growth Rate (Future 3Y To 5Y Est) Related Terms

Thank you for viewing the detailed overview of Eterna Therapeutics's Total Revenue Growth Rate (Future 3Y To 5Y Est) provided by GuruFocus.com. Please click on the following links to see related term pages.

Eterna Therapeutics (Eterna Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Eterna Therapeutics Inc (NAS:ERNA) » Definitions » Total Revenue Growth Rate (Future 3Y To 5Y Est)

Comparable Companies

Traded in Other Exchanges

N/A

Address

1035 Cambridge Street, Suite 18A, Cambridge, MA, USA, 02141

Website

https://www.eternatx.com

Eterna Therapeutics Inc is a biopharmaceutical company. The company develops transformational new medicines using various cell engineering technology. It is engaged in developing breakthrough mRNA cell engineering technologies to repair cellular dysfunction and treat a range of therapeutic indications. With its strategic partners, the group is developing nucleic acid and cell therapies that can significantly improve the health outcomes of patients with high unmet medical needs.

Executives

Dorothy J Clarke	director	C/O ETERNA THERAPEUTICS INC., 1035 CAMBRIDGE STREET, STE. 18A, CAMBRIDGE MA 02141
Charles Cherington	10 percent owner	ONE BOW STREET, CAMBRIDGE MA 02138
Brant Binder	director	C/O TRUST CO OF THE SWEST, 200 PARK AVE SUITE 220, NEW YORK NY 01066
Richard W Wagner	director	C/O PRAECIS PHARMACEUTICALS INC, 830 WINTER ST, WALTHAM MA 02451
Curtis W Huft	10 percent owner	4510 LAMESA HWY, SNYDER TX 79549
Freebird Partners Lp	10 percent owner	2800 POST OAK BLVD., SUITE 2000, HOUSTON TX 77056
Freebird Investments Llc	10 percent owner	2800 POST OAK BLVD., SUITE 2000, HOUSTON TX 77056
John D Halpern	10 percent owner
Nicholas Jason Singer	director	1395 BRICKELL AVENUE, SUITE 800, MIAMI FL 33131
William A. Wexler	director	12 GILL STREET, SUITE 4650, WOBURN MA 01801
Gregory Fiore	director	10355 SCIENCE CENTER DRIVE, SUITE 150, SAN DIEGO CA 92121
Andrew C. Jackson	officer: Chief Financial Officer	11988 EL CAMINO REAL STE. 650, SAN DIEGO CA 92130
Matthew Angel	officer: Interim President and CEO	10531 4S COMMONS DRIVE, SUITE 160-550, SAN DIEGO CA 92127
Heather B Redman	director	TWO NORTH NINTH STREET, ALLENTOWN PA 18101
Erin S. Enright	director	666 PLAINSBORO ROAD, PLAINSBORO NJ 08536